Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates (Einstein Jr)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02564718
Recruitment Status : Completed
First Posted : October 1, 2015
Results First Posted : July 10, 2018
Last Update Posted : July 10, 2018
Sponsor:
Collaborator:
Janssen Research & Development, LLC
Information provided by (Responsible Party):
Bayer

Brief Summary:
The purpose of this study is to find out whether rivaroxaban is safe and effective to use in children age newborn to less than 6 months and how long it stays in the body and how it is used in the body. Safety will be assessed by looking at the incidence and types of bleeding events. There will also be a check for worsening of blood clots.

Condition or disease Intervention/treatment Phase
Thromboembolism Drug: Rivaroxaban (Xarelto, BAY59-7939) Phase 1 Phase 2

Detailed Description:

Neonates and infants aged less than 6 months who pass the screen of in- and exclusion criteria, who have been treated for at least five days with heparin and /or vitamin K antagonist (VKA) for confirmed symptomatic or asymptomatic arterial or venous thrombosis are eligible for the study. Study treatment consists of a 7-day treatment with an age- and body weight-adjusted three times daily, approximately 8 hours apart oral rivaroxaban dosing to achieve a similar exposure as that observed in adults treated for venous thromboembolism (VTE) with 20 mg rivaroxaban once daily. Rivaroxaban will be provided as granules for preparation of an oral suspension (1 mg/mL after re-suspension) using a t.i.d. regimen with 8-hour intervals. An ultrasound will be performed before starting rivaroxaban at treatment day 1 and after the end of rivaroxaban treatment at day 8. The last dose of rivaroxaban treatment will be followed by a 30-day post study treatment period, regardless of the duration of study drug administration. After cessation of rivaroxaban, it is at the investigator's discretion to continue with anticoagulants. The principal safety outcome is the combination of major and clinically relevant non-major bleeding. The efficacy outcome is the composite of all symptomatic recurrent thromboembolism and asymptomatic deterioration in thrombotic burden on repeat imaging. All suspected recurrent thromboembolism, asymptomatic deterioration in thrombotic burden on repeat imaging, deaths, as well as all episodes of bleeding will be evaluated by a central independent adjudication committee (CIAC). Adjudication results will be the basis for the final analyses.

For all children, visits are scheduled at regular time points (see Table 1). Enrolled children who are not treated or those with premature discontinuation of rivaroxaban will at least be seen at the end of the study treatment period. During all contacts, the treatment and clinical course of the child will be evaluated. Children with suspected efficacy or safety outcomes will undergo confirmatory testing as per standard of care. Blood samples for pharmacokinetic (PK)/pharmacodynamics (PD) will be taken at defined time points (see Table 2).

An Independent Data Monitoring Committee (DMC) will monitor the children's safety during the study and give recommendations to the steering committee.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: 7-day Study of the Safety, Efficacy and the Pharmacokinetic and Pharmacodynamic Properties of Oral Rivaroxaban in Children From Birth to Less Than 6 Months With Arterial or Venous Thrombosis
Actual Study Start Date : November 19, 2015
Actual Primary Completion Date : December 18, 2017
Actual Study Completion Date : December 18, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Blood Clots
Drug Information available for: Rivaroxaban

Arm Intervention/treatment
Experimental: Arm 1
Rivaroxaban oral suspension from granules will be dosed according to body weight as oral 0.1% suspension (1 mg/mL)
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Body weight adjusted dosing of rivaroxaban to achieve a similar exposure in the range as that observed in adults treated for venous thromboembolism (VTE) with 20 mg once daily.




Primary Outcome Measures :
  1. Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 1 [ Time Frame: 30 minutes to 1.5 hours post-dose; 2 to 4 hours post-dose (bid dosing) and 30 minutes to 3 hours post-dose; 7 to 8 hours post-dose on Day 1 (tid dosing) ]
    Concentration of pharmacokinetic parameters of rivaroxaban in plasma was evaluated.

  2. Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 3 [ Time Frame: 2 to 8 hours post-dose (bid dosing) and 30 minutes to 3 hours post-dose; 7 to 8 hours post-dose on Day 3 (tid dosing) ]
    Concentration of pharmacokinetic parameters of rivaroxaban in plasma was evaluated.

  3. Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 8 [ Time Frame: 10 to 16 hours post-dose on Day 8 (bid dosing) ]
    Concentration of pharmacokinetic parameters of rivaroxaban in plasma was evaluated.

  4. Change From Baseline in Prothrombin Time at Day 1 [ Time Frame: 10-16 hours post-dose on Day 8 (baseline), 2-4 hours after the first dose on Day 1 (bid dosing) and 7-8 hours after the first dose on Day 1 (tid dosing) ]
    Prothrombin time is a global clotting test used for the assessment of the extrinsic pathway of the blood coagulation cascade.

  5. Change From Baseline in Prothrombin Time at Day 3 [ Time Frame: 10-16 hours post-dose on Day 8 (baseline), 2-8 hours post-dose on Day 3 (bid dosing) and 0.5-3 hours post-dose on Day 3 (tid dosing) ]
    Prothrombin time is a global clotting test used for the assessment of the extrinsic pathway of the blood coagulation cascade.

  6. Change From Baseline in Activated Partial Thromboplastin Time (aPTT) at Day 1 [ Time Frame: 10-16 hours post-dose on Day 8 (baseline), 2-4 hours after the first dose on Day 1 (bid dosing) and 7-8 hours after the first dose on Day 1 (tid dosing) ]
    The Activated partial thromboplastin time (aPTT) is a screening test for the intrinsic pathway and is sensitive for deficiencies of factors I, II, V, VIII, IX, X, XI and XII.

  7. Change From Baseline in Activated Partial Thromboplastin Time (aPTT) at Day 3 [ Time Frame: 10-16 hours post-dose on Day 8 (baseline), 2-8 hours post-dose on Day 3 (bid dosing) and 0.5-3 hours post-dose on Day 3 (tid dosing) ]
    The Activated partial thromboplastin time (aPTT) is a screening test for the intrinsic pathway and is sensitive for deficiencies of factors I, II, V, VIII, IX, X, XI and XII.

  8. Anti-factor Xa Activity (Anti-Xa) Values at Day 1 [ Time Frame: 2-4 hours after the first dose on Day 1 (bid dosing) and 7-8 hours after the first dose on Day 1 (tid dosing) ]
    The individual anti-Factor Xa activity was determined ex-vivo using a photometric method.

  9. Anti-factor Xa Activity (Anti-Xa) Values at Day 3 [ Time Frame: 2-8 hours post-dose on Day 3 (bid dosing) and 0.5-3 hours post-dose on Day 3 (tid dosing) ]
    The individual anti-Factor Xa activity was determined ex-vivo using a photometric method.

  10. Anti-factor Xa Activity (Anti-Xa) Values at Day 8 [ Time Frame: 10-16 hours post-dose on Day 8 (both bid and tid dosing) ]
    The individual anti-Factor Xa activity was determined ex-vivo using a photometric method.


Secondary Outcome Measures :
  1. Number of Participants With Major and Clinically Relevant Non-Major Bleeding Events [ Time Frame: From start of study drug administration until 30-day post study treatment period ]
    Central independent adjudication committee (CIAC) classified bleeding as follows: Major bleeding is defined as overt bleeding and •associated with a fall in hemoglobin of 2 gram/deciliter (g/dL) or more, •leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults, or •occurring in a critical site, example: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or •contributing to death. Clinically relevant non-major bleeding is defined as overt bleeding not meeting the criteria for major bleeding, but associated with: •medical intervention, or •unscheduled contact (visit or telephone call) with a physician, or •cessation (temporary) of study treatment, or •discomfort for the child such as pain

  2. Number of Participants With Symptomatic Recurrent Venous Thromboembolism and Asymptomatic Deterioration in Thrombotic Burden on Repeat Imaging [ Time Frame: From start of study drug administration until 30-day post study treatment period ]
    Symptomatic recurrence of thromboembolism and asymptomatic deterioration was documented using the appropriate imaging test and confirmed by CIAC which was unaware of treatment assignment. Asymptomatic deterioration in thrombotic burden on repeat imaging, as assessed by the CIAC. Adjudication results were the basis for the final analyses.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 6 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Children from birth to less than 6 months with documented symptomatic or asymptomatic venous or arterial thrombosis who have been treated with anticoagulant therapy for at least 5 days.
  • Gestational age at birth of at least 37 weeks.
  • Hemoglobin, platelets, creatinine, ALT and total and direct bilirubin assessed within 10 days prior to enrollment.
  • Oral feeding/nasogastric/gastric feeding for at least 10 days.
  • Informed consent provided.
  • Body weight >2600 g

Exclusion Criteria:

  • Active bleeding or high risk for bleeding contraindicating anticoagulant therapy, including history of intra-ventricular bleeding.
  • Symptomatic progression of thrombosis during preceding anticoagulant treatment.
  • Planned invasive procedures, including lumbar puncture and removal of non-peripherally placed central lines during study treatment.
  • Hepatic disease which is associated with either: coagulopathy leading to a clinically relevant bleeding risk, or alanine aminotransferase (ALT) > 5x upper level of normal (ULN) or total bilirubin (TB) > 2x ULN with direct bilirubin > 20% of the total.
  • Creatinine >1.5 times of normal.
  • Uncontrolled Hypertension defined as >95th percentile.
  • History of gastrointestinal disease or surgery associated with impaired absorption.
  • Platelet count <100 x 109/L.
  • Concomitant use of strong inhibitors of both cytochrome P450 isoenzyme 3A4 (CYP3A4) and P-glycoprotein (P-gp), e.g. all human immunodeficiency virus protease inhibitors and the following azole-antimycotics agents: ketoconazole, itraconazole, voriconazole, posaconazole, if used systemically (fluconazole is allowed)
  • Concomitant use of strong inducers of CYP3A4, e.g. rifampicin, rifabutin, phenobarbital, phenytoin and carbamazepine
  • Indication for anticoagulant therapy other than current thrombosis.
  • Indication for antiplatelet therapy or non-steroid anti-inflammatory drug (NSAID) therapy. Incidental use is allowed.
  • Hypersensitivity to rivaroxaban or its excipients.
  • Participation in a study with an investigational drug or medical device within 30 days prior to enrollment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02564718


Locations
Layout table for location information
Austria
Wien, Austria, 1090
France
Montpellier, France, 34059
Germany
Erlangen, Germany, 91052
Israel
Ramat Gan, Israel, 5262000
Italy
Milano, Lombardia, Italy, 20122
Spain
Barcelona, Spain, 08035
Madrid, Spain, 28007
Madrid, Spain, 28046
Turkey
Izmir, Turkey, 35-100
Sponsors and Collaborators
Bayer
Janssen Research & Development, LLC
Investigators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
  Study Documents (Full-Text)

Documents provided by Bayer:
Statistical Analysis Plan  [PDF] February 9, 2016
Study Protocol  [PDF] November 15, 2016

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT02564718    
Other Study ID Numbers: 17618
2014-002385-74 ( EudraCT Number )
First Posted: October 1, 2015    Key Record Dates
Results First Posted: July 10, 2018
Last Update Posted: July 10, 2018
Last Verified: June 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Bayer:
Pediatric
Additional relevant MeSH terms:
Layout table for MeSH terms
Thrombosis
Thromboembolism
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Rivaroxaban
Factor Xa Inhibitors
Antithrombins
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anticoagulants